Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Standard
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. / Pui, Ching-Hon; Yang, Jun J; Hunger, Stephen P; Pieters, Rob; Schrappe, Martin; Biondi, Andrea; Vora, Ajay; Baruchel, André; Silverman, Lewis B; Schmiegelow, Kjeld; Escherich, Gabriele; Horibe, Keizo; Benoit, Yves C M; Izraeli, Shai; Yeoh, Allen Eng Juh; Liang, Der-Cherng; Downing, James R; Evans, William E; Relling, Mary V; Mullighan, Charles G.
in: J CLIN ONCOL, Jahrgang 33, Nr. 27, 20.09.2015, S. 2938-48.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
AU - Pui, Ching-Hon
AU - Yang, Jun J
AU - Hunger, Stephen P
AU - Pieters, Rob
AU - Schrappe, Martin
AU - Biondi, Andrea
AU - Vora, Ajay
AU - Baruchel, André
AU - Silverman, Lewis B
AU - Schmiegelow, Kjeld
AU - Escherich, Gabriele
AU - Horibe, Keizo
AU - Benoit, Yves C M
AU - Izraeli, Shai
AU - Yeoh, Allen Eng Juh
AU - Liang, Der-Cherng
AU - Downing, James R
AU - Evans, William E
AU - Relling, Mary V
AU - Mullighan, Charles G
N1 - © 2015 by American Society of Clinical Oncology.
PY - 2015/9/20
Y1 - 2015/9/20
N2 - PURPOSE: To review the impact of collaborative studies on advances in the biology and treatment of acute lymphoblastic leukemia (ALL) in children and adolescents.METHODS: A review of English literature on childhood ALL focusing on collaborative studies was performed. The resulting article was reviewed and revised by the committee chairs of the major ALL study groups.RESULTS: With long-term survival rates for ALL approaching 90% and the advent of high-resolution genome-wide analyses, several international study groups or consortia were established to conduct collaborative research to further improve outcome. As a result, treatment strategies have been improved for several subtypes of ALL, such as infant, MLL-rearranged, Philadelphia chromosome-positive, and Philadelphia chromosome-like ALL. Many recurrent genetic abnormalities that respond to tyrosine kinase inhibitors and multiple genetic determinants of drug resistance and toxicities have been identified to help develop targeted therapy. Several genetic polymorphisms have been recognized that show susceptibility to developing ALL and that help explain the racial/ethnic differences in the incidence of ALL.CONCLUSION: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.
AB - PURPOSE: To review the impact of collaborative studies on advances in the biology and treatment of acute lymphoblastic leukemia (ALL) in children and adolescents.METHODS: A review of English literature on childhood ALL focusing on collaborative studies was performed. The resulting article was reviewed and revised by the committee chairs of the major ALL study groups.RESULTS: With long-term survival rates for ALL approaching 90% and the advent of high-resolution genome-wide analyses, several international study groups or consortia were established to conduct collaborative research to further improve outcome. As a result, treatment strategies have been improved for several subtypes of ALL, such as infant, MLL-rearranged, Philadelphia chromosome-positive, and Philadelphia chromosome-like ALL. Many recurrent genetic abnormalities that respond to tyrosine kinase inhibitors and multiple genetic determinants of drug resistance and toxicities have been identified to help develop targeted therapy. Several genetic polymorphisms have been recognized that show susceptibility to developing ALL and that help explain the racial/ethnic differences in the incidence of ALL.CONCLUSION: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.
KW - Adolescent
KW - Age of Onset
KW - Biomarkers, Tumor
KW - Child
KW - Child, Preschool
KW - Cooperative Behavior
KW - Diffusion of Innovation
KW - Genetic Predisposition to Disease
KW - Genetic Testing
KW - History, 20th Century
KW - History, 21st Century
KW - Humans
KW - Infant
KW - Infant, Newborn
KW - Interdisciplinary Communication
KW - International Cooperation
KW - Medical Oncology
KW - Pediatrics
KW - Phenotype
KW - Precision Medicine
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma
KW - Predictive Value of Tests
KW - Survivors
KW - Time Factors
KW - Treatment Outcome
U2 - 10.1200/JCO.2014.59.1636
DO - 10.1200/JCO.2014.59.1636
M3 - SCORING: Journal article
C2 - 26304874
VL - 33
SP - 2938
EP - 2948
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 27
ER -